Your browser doesn't support javascript.
loading
Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.
Kouyos, Roger D; Rusert, Peter; Kadelka, Claus; Huber, Michael; Marzel, Alex; Ebner, Hanna; Schanz, Merle; Liechti, Thomas; Friedrich, Nikolas; Braun, Dominique L; Scherrer, Alexandra U; Weber, Jacqueline; Uhr, Therese; Baumann, Nicolas S; Leemann, Christine; Kuster, Herbert; Chave, Jean-Philippe; Cavassini, Matthias; Bernasconi, Enos; Hoffmann, Matthias; Calmy, Alexandra; Battegay, Manuel; Rauch, Andri; Yerly, Sabine; Aubert, Vincent; Klimkait, Thomas; Böni, Jürg; Metzner, Karin J; Günthard, Huldrych F; Trkola, Alexandra.
Afiliação
  • Kouyos RD; Institute of Medical Virology, University of Zurich, Zurich, Switzerland. roger.kouyos@usz.ch.
  • Rusert P; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. roger.kouyos@usz.ch.
  • Kadelka C; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Huber M; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Marzel A; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Ebner H; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Schanz M; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Liechti T; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Friedrich N; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Braun DL; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Scherrer AU; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Weber J; ImmunoTechnology Section, Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USA.
  • Uhr T; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Baumann NS; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Leemann C; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Kuster H; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Chave JP; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Cavassini M; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Bernasconi E; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Hoffmann M; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Calmy A; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Battegay M; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Rauch A; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Yerly S; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Aubert V; Clinique de La Source, Lausanne, Switzerland.
  • Klimkait T; Division of Infectious Diseases, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland.
  • Böni J; Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland.
  • Metzner KJ; Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
  • Günthard HF; Division of Infectious Diseases, University Hospital Geneva, University of Geneva, Geneva, Switzerland.
  • Trkola A; Division of Infectious Diseases, University Hospital Basel, University of Basel, Basel, Switzerland.
Nature ; 561(7723): 406-410, 2018 09.
Article em En | MEDLINE | ID: mdl-30202088
ABSTRACT
Understanding the determinants of broadly neutralizing antibody (bNAb) evolution is crucial for the development of bNAb-based HIV vaccines1. Despite emerging information on cofactors that promote bNAb evolution in natural HIV-1 infections, in which the induction of bNAbs is genuinely rare2, information on the impact of the infecting virus strain on determining the breadth and specificity of the antibody responses to HIV-1 is lacking. Here we analyse the influence of viral antigens in shaping antibody responses in humans. We call the ability of a virus strain to induce similar antibody responses across different hosts its antibody-imprinting capacity, which from an evolutionary biology perspective corresponds to the viral heritability of the antibody responses. Analysis of 53 measured parameters of HIV-1-binding and neutralizing antibody responses in a cohort of 303 HIV-1 transmission pairs (individuals who harboured highly related HIV-1 strains and were putative direct transmission partners or members of an HIV-1 transmission chain) revealed that the effect of the infecting virus on the outcome of the bNAb response is moderate in magnitude but highly significant. We introduce the concept of bNAb-imprinting viruses and provide evidence for the existence of such viruses in a systematic screening of our cohort. The bNAb-imprinting capacity can be substantial, as indicated by a transmission pair with highly similar HIV-1 antibody responses and strong bNAb activity. Identification of viruses that have bNAb-imprinting capacities and their characterization may thus provide the potential to develop lead immunogens.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / Infecções por HIV / HIV-1 / Anticorpos Neutralizantes Limite: Female / Humans / Male Idioma: En Revista: Nature Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Suíça
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / Infecções por HIV / HIV-1 / Anticorpos Neutralizantes Limite: Female / Humans / Male Idioma: En Revista: Nature Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Suíça